Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Uematsu, Takayoshi; Kasami, Masako; Watanabe, Junichiro; Takahashi, Kaoru; Yamasaki, Seiji; Tanaka, Kumiko; Tadokoro, Yukiko; Ogiya, Akiko

doi:10.1007/s12282-010-0211-z

Cited by 41 publications

(31 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,5,6,8–13,25,28,29 Paradoxically, higher-risk molecular profiles (HER2+ or TN, for example) have been shown to be associated with higher likelihood of achieving a complete pathologic response, which in turn predicts better disease-free survival, as reported by the I-SPY Trial investigators and others. 5,6,30,31 Failure to achieve a complete or near complete pathologic response in these same patients is associated with increased risk of recurrence-free survival.…”

Section: Discussionmentioning

confidence: 87%

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

et al. 2014

View full text Add to dashboard Cite

Background Increasingly, women with stage 2 and 3 breast cancers receive neoadjuvant therapy, after which many are eligible for breast-conserving surgery (BCS). The question often arises as to whether BCS, if achievable, provides adequate local control. We report the results of local recurrence (LR) from the I-SPY 1 Trial in the setting of maximal multidisciplinary treatment where approximately 50 % of patients were treated with BCS. Methods We analyzed data from the I-SPY 1 Trial. Women with tumors ≥3 cm from nine clinical breast centers received neoadjuvant doxorubicin, cyclophosphamide and paclitaxel followed by definitive surgical therapy, and radiation at physician discretion. LR following mastectomy and BCS were analyzed in relation to clinical characteristics and response to therapy as measured by residual cancer burden. Results Of the 237 patients enrolled in the I-SPY 1 Trial, 206 were available for analysis. Median tumor size was 6.0 cm, and median follow-up was 3.9 years. Fourteen patients (7 %) had LR and 45 (22 %) had distant recurrence (DR). Of the 14 patients with LR, nine had synchronous DR; one had DR > 2 years later. Only four (2 % of evaluable patients) had LR alone. The rate of LR was low after mastectomy and after BCS, even in the setting of significant residual disease. Conclusions Overall, these patients at high risk for early recurrence, treated with maximal multidisciplinary treatment, had low LR. Recurrence was associated with aggressive biological features such as more advanced stage at presentation, where LR occurs most frequently in the setting of DR.

show abstract

Section: Discussionmentioning

confidence: 87%

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Lymphovascular invasion has been reported to have prognostic significance because its presence is most likely responsible for lymph node metastasis that is the most important prognostic variable for patients with breast cancer [23]. Lymphovascular invasion is very useful for predicting the pathological response and outcome of patients who receive NAC [24,25]. In addition, lymphovascular invasion is a risk estimation factor for sentinel lymph node metastasis, but it can be evaluated only after surgery [26].…”

Section: Discussionmentioning

confidence: 99%

Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3 T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?

2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some studies have shown that LVI is associated with “chemoresistant” cancers[25] and that its absence on core biopsies is associated with a complete pathological response (pCR) and improved survival. [7] However, few studies have examined the role of LVI as an independent predictor of survival with adriamycin (A) and taxane (T)-based NAC regimens.…”

Section: Introductionmentioning

confidence: 99%

Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy

Liu

Saraf

Lee

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background Various prognostic indicators have been investigated in neoadjuvant chemotherapy (NAC) treated invasive breast cancer (BC). Our study examines if lymphovascular invasion (LVI) is an independent predictor of survival in women receiving NAC. Methods We performed a retrospective analysis in 166 women with operable invasive BC who underwent adriamycin (A) and taxane (T)-based NAC between 2000-2013. Presence of LVI was noted in breast excisions following NAC. Associations between progression-free and overall survival and LVI and other clinicopathologic variables were assessed. Results Median follow-up was 31 months (range 1.4-153 months) with a total of 56 events and 24 deaths from any cause. LVI was found in 74 of 166 patients (45%). In univariate analysis, presence of LVI was associated with worse progression-free survival (HR 3.37 95% CI 1.87-6.06, p<0.01) and overall survival (HR 4.35, 95% CI 1.61-11.79, p<0.01). In multivariate models adjusting for breast cancer subtype, LVI was significantly associated with a decrease in progression-free survival (HR 3.76 95% CI 2.07-6.83, p<0.01) and overall survival (HR 5.70 95% CI 2.08-15.64, p<0.01). When stratified by subtype, those with hormone receptor or HER2 positive BCs with no LVI had the most favorable progression-free and overall survival. Those with both LVI and triple negative BC had the worst progression-free and overall survival. Conclusions LVI is an important prognostic marker and is associated with worse clinical outcome in breast cancer patients receiving NAC.

show abstract

Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Abstract: Lymphovascular invasion degree is one of the important factors to predict NAC efficacy for breast cancer.

Cited by 41 publications

References 18 publications

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3 T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?

Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy

Contact Info

Product

Resources

About